Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...

Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...

Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...

On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock.

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

Shares of NASDAQ KRRO opened at $77.00 on Thursday. Korro Bio has a 12-month low of $9.15 and a 12-month high of $98.00. The stock has a fifty day moving average price of $40.45 and a 200 day ...

On Monday, RBC Capital Markets adjusted its outlook for Korro Bio Inc. (NASDAQ:KRRO) shares, raising the stock's price target to $105 from $95, while retaining an Outperform rating. The increase ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...